{"id":965259,"date":"2026-05-20T09:30:05","date_gmt":"2026-05-20T13:30:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/"},"modified":"2026-05-20T09:30:05","modified_gmt":"2026-05-20T13:30:05","slug":"regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/","title":{"rendered":"REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p>\nREGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud<\/p>\n<p><i>Regeneron executives told investors Fianlimab + Libtayo was one of their \u201cpotential blockbusters&#8221; just weeks before the drug combination\u2019s Phase 3 melanoma trial failed its primary endpoint against Keytruda.<\/i><\/p>\n<p>NEW YORK&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRegeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo in first-line metastatic melanoma failed to meet its primary endpoint versus Merck&#8217;s Keytruda. Shareholders who lost money on REGN are encouraged to <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fzlk.com%2Fcases%2Fregeneron-pharmaceuticals-inc-lawsuit-submission-form%3Fprid%3D186546%26wire%3D2&amp;esheet=54538585&amp;newsitemid=20260520385200&amp;lan=en-US&amp;anchor=submit+their+information+here&amp;index=1&amp;md5=4f9cf69827fef196a680f0a0a8b49318\">submit their information here<\/a>. You may also contact Joseph E. Levi, Esq. via email at <a rel=\"nofollow\" href=\"mailto:jlevi@levikorsinsky.com\">jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>\n<p>\nDuring the Q1 2026 earnings call on April 29, 2026, Regeneron executives stated that the Phase 3 melanoma study &#8220;remains on track with results expected later in the second quarter of this year.&#8221; Chief Science Officer George D. Yancopoulos highlighted \u201cfianlimab Libtayo\u201d as one among the company\u2019s \u201cpotential blockbusters,\u201d noting it was \u201chard to think of a more exciting pipeline in the entire industry.\u201d Less than three weeks later, Regeneron announced the phase 3 trial for the drug combination had failed.<\/p>\n<p>\nThe investigation concerns whether Regeneron&#8217;s statements regarding the fianlimab trial&#8217;s progress adequately reflected the information available to management at the time they were made. If you purchased Regeneron shares and suffered a loss, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fzlk.com%2Fcases%2Fregeneron-pharmaceuticals-inc-lawsuit-submission-form%3Fprid%3D186546%26wire%3D2&amp;esheet=54538585&amp;newsitemid=20260520385200&amp;lan=en-US&amp;anchor=click+here+to+discuss+your+legal+rights&amp;index=2&amp;md5=e160e3ec1d974c684576c40bf36987a8\">click here to discuss your legal rights<\/a>. You may also contact Joseph E. Levi, Esq. via email at <a rel=\"nofollow\" href=\"mailto:jlevi@levikorsinsky.com\">jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>\n<p>\nWHY LEVI &amp; KORSINSKY &#8212; Ranked in ISS Securities Class Action Services&#8217; Top 50 Report for seven consecutive years, Levi &amp; Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.<\/p>\n<p>\nFrequently Asked Questions About the REGN Investigation<\/p>\n<p><b>Q: Who is conducting the REGN investigation?<\/b> A: Levi &amp; Korsinsky, LLP is investigating potential securities law violations on behalf of investors who purchased REGN securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.<\/p>\n<p><b>Q: Which statements are being investigated as potentially misleading?<\/b> A: The investigation concerns whether Regeneron made materially false or misleading statements regarding the potential, progress, and prospects of its Phase 3 fianlimab melanoma trial. When the trial failure was revealed, the stock price declined sharply.<\/p>\n<p><b>Q: Who is eligible to participate in the REGN investigation?<\/b> A: Investors who purchased REGN stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses &#8212; not on whether you still hold the shares.<\/p>\n<p><b>Q: What do REGN investors need to do right now?<\/b> A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi &amp; Korsinsky for a free, no-obligation evaluation at <a rel=\"nofollow\" href=\"mailto:jlevi@levikorsinsky.com\">jlevi@levikorsinsky.com<\/a> or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.<\/p>\n<p><b>Q: What if I already sold my REGN shares &#8212; can I still recover losses?<\/b> A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought REGN and sold at a loss may still participate in the investigation.<\/p>\n<p><b>Q: What does it cost me to participate?<\/b> A: Nothing. Securities investigations are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.<\/p>\n<p><b>Q: Do I need to go to court or give testimony?<\/b> A: No. Participating in the investigation does not require court appearances or depositions.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260520385200r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260520385200\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260520385200\/en\/<\/a><\/span><\/p>\n<p>\nLevi &amp; Korsinsky, LLP<br \/>\n<br \/>Joseph E. Levi, Esq.<br \/>\n<br \/>Ed Korsinsky, Esq.<br \/>\n<br \/>33 Whitehall Street, 27th Floor<br \/>\n<br \/>New York, NY 10004<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jlevi@levikorsinsky.com\">jlevi@levikorsinsky.com<br \/>\n<\/a><br \/>Tel: (212) 363-7500<br \/>\n<br \/>Fax: (212) 363-7171<\/p>\n<p><b>KEYWORDS:<\/b> New York United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260520385200\/en\/2742089\/3\/Gradient_%28Square_Mark%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud Regeneron executives told investors Fianlimab + Libtayo was one of their \u201cpotential blockbusters&#8221; just weeks before the drug combination\u2019s Phase 3 melanoma trial failed its primary endpoint against Keytruda. NEW YORK&#8211;(BUSINESS WIRE)&#8211; Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo in first-line metastatic melanoma failed to meet its primary endpoint versus Merck&#8217;s Keytruda. Shareholders who lost money on REGN are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. During the Q1 2026 earnings &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-965259","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud Regeneron executives told investors Fianlimab + Libtayo was one of their \u201cpotential blockbusters&#8221; just weeks before the drug combination\u2019s Phase 3 melanoma trial failed its primary endpoint against Keytruda. NEW YORK&#8211;(BUSINESS WIRE)&#8211; Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo in first-line metastatic melanoma failed to meet its primary endpoint versus Merck&#8217;s Keytruda. Shareholders who lost money on REGN are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. During the Q1 2026 earnings &hellip; Continue reading &quot;REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-20T13:30:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260520385200r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud\",\"datePublished\":\"2026-05-20T13:30:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\\\/\"},\"wordCount\":660,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260520385200r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\\\/\",\"name\":\"REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260520385200r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-05-20T13:30:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260520385200r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260520385200r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/","og_locale":"en_US","og_type":"article","og_title":"REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud - Market Newsdesk","og_description":"REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud Regeneron executives told investors Fianlimab + Libtayo was one of their \u201cpotential blockbusters&#8221; just weeks before the drug combination\u2019s Phase 3 melanoma trial failed its primary endpoint against Keytruda. NEW YORK&#8211;(BUSINESS WIRE)&#8211; Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo in first-line metastatic melanoma failed to meet its primary endpoint versus Merck&#8217;s Keytruda. Shareholders who lost money on REGN are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. During the Q1 2026 earnings &hellip; Continue reading \"REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-20T13:30:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260520385200r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud","datePublished":"2026-05-20T13:30:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/"},"wordCount":660,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260520385200r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/","name":"REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260520385200r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-05-20T13:30:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260520385200r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260520385200r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regn-investor-alert-levi-korsinsky-investigates-regeneron-pharmaceuticals-inc-regn-for-potential-securities-fraud\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"REGN Investor Alert: Levi &amp; Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=965259"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965259\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=965259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=965259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=965259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}